Ascentage Pharma swings to RMB591m loss despite sales growth

Ascentage Pharma Group International reported a net loss of RMB590.8 million for the six months ended June 30, 2025, compared to a RMB162.8 million profit in the same period of 2024.

The loss was primarily driven by a decrease in intellectual property revenue, which stood at RMB678.4 million in the prior year. Overall revenue declined to RMB233.7 million from RMB823.7 million.

However, product sales of Olverembatinib in China increased 93% to RMB217.4 million. R&D expenses rose 19% to RMB528.6 million.